KINIKSA _2c_final - Copy.jpg
Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis
16 nov. 2020 08h00 HE | Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate...
KINIKSA _2c_final - Copy.jpg
Kiniksa Announces Phase 2 Clinical Data from Vixarelimab in Prurigo Nodularis to be Presented at European Academy of Dermatology and Venereology Virtual Congress
29 oct. 2020 08h00 HE | Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate...
KINIKSA _2c_final - Copy.jpg
Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint
22 avr. 2020 08h00 HE | Kiniksa Pharmaceuticals, Ltd.
- Statistically significant primary efficacy endpoint of reduction in weekly-average Worst-Itch Numeric Rating Scale (WI-NRS) at Week 8 -- Statistically significant secondary efficacy endpoint of...
TreviLogo.png
TREVI THERAPEUTICS TO PRESENT AT NEEDHAM HEALTHCARE CONFERENCE
08 avr. 2020 16h05 HE | Trevi Therapeutics
NEW HAVEN, Conn., April 08, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
TreviLogo.png
Trevi Therapeutics Announces Election of James V. Cassella, Ph.D. to Board of Directors
18 févr. 2020 16h05 HE | Trevi Therapeutics
NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER...
TreviLogo.png
Trevi Therapeutics Announces Third Quarter 2019 Financial Results and Recent Business Developments
14 nov. 2019 16h05 HE | Trevi Therapeutics
Advancement of Nalbuphine ER in Clinical Development for Three Indications Cash Position of $63.5 Million Expected to Fund Operations Through At Least Q1 2021 NEW HAVEN, Conn., Nov. 14, 2019 ...
TreviLogo.png
Trevi Therapeutics to Present at Stifel Healthcare Conference
13 nov. 2019 17h01 HE | Trevi Therapeutics
NEW HAVEN, Conn., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
TreviLogo.png
Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
18 juin 2019 16h05 HE | Trevi Therapeutics
NEW HAVEN, Conn., June 18, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
KINIKSA _2c_final - Copy.jpg
Kiniksa Presents Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology
13 mai 2019 07h30 HE | Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, May 13, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
TreviLogo.png
Trevi Therapeutics Announces Pricing of Initial Public Offering
07 mai 2019 13h22 HE | Trevi Therapeutics
NEW HAVEN, Conn., May 07, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to...